Investor Amgen Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Amgen Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-08-23 13G/A NAMS / NewAmsterdam Pharma Company N.V. 0
2023-09-27 13D NMRA / Neumora Therapeutics, Inc. 35,368,653
2023-02-10 13G/A / JASPER THERAPEUTICS INC 2,700,000 1,009,929
2022-12-02 13G NAMS / NewAmsterdam Pharma Company N.V. 4,910,000
2022-01-12 13G VIGL / Vigil Neuroscience, Inc. 3,206,281
2021-10-01 13G / JASPER THERAPEUTICS INC 2,700,000
2021-02-05 13G/A AKRO / Akero Therapeutics, Inc. 1,905,698 1,508,375
2021-02-05 13G/A PRVB / Provention Bio Inc 2,500,000 2,500,000
2020-07-16 13D/A BGNE / BeiGene, Ltd. - Depositary Receipt (Common Stock) 206,635,013 236,249,845
2020-02-10 13G/A KZR / Kezar Life Sciences, Inc. 504,438 504,438
2020-02-10 13G AKRO / Akero Therapeutics, Inc. 1,905,698 1,905,698
2020-02-08 13G AKRO / Akero Therapeutics, Inc. 1,905,698
2020-02-08 13G/A KZR / Kezar Life Sciences, Inc. 1,121,384 504,438
2020-01-08 13D BGNE / BeiGene, Ltd. - Depositary Receipt (Common Stock) 206,635,013
2019-09-25 13G PRVB / Provention Bio Inc 2,500,000
2019-02-08 13G KZR / Kezar Life Sciences, Inc. 1,121,384
2018-12-28 13G/A ADXS / Ayala Pharmaceuticals, Inc. 3,047,446 3,047,446
2017-08-02 13G/A UNIS / Unilife Corp 0
2017-02-07 13G/A UNIS / Unilife Corp
2017-02-07 13G/A ADXS / Ayala Pharmaceuticals, Inc. 3,047,446 3,047,446
2017-02-07 13G/A ATRA / Atara Biotherapeutics, Inc. 1,468,501 1,403,501
2016-09-08 13D/A CYTK / Cytokinetics, Incorporated 1,984,901
2016-08-02 13G ADXS / Ayala Pharmaceuticals, Inc. 3,047,446
2016-03-03 13G UNIS / Unilife Corp
2015-04-01 13G ATRA / Atara Biotherapeutics, Inc. 1,468,501
2014-03-06 13D/A CYTK / Cytokinetics, Incorporated 1,984,901
2013-06-18 13D CYTK / Cytokinetics, Incorporated 11,909,406
2013-03-21 13D/A CYTK / Cytokinetics, Incorporated 3,484,806
2012-02-03 13D MITI / Mitesco, Inc. 12,986,468
2000-04-05 13D/A REGN / Regeneron Pharmaceuticals, Inc. 4,916,808
2000-03-07 13D/A REGN / Regeneron Pharmaceuticals, Inc. 4,916,808
1996-04-18 13D/A REGN / Regeneron Pharmaceuticals, Inc. 5,138,766
1996-03-05 13D/A REGN / Regeneron Pharmaceuticals, Inc. 1,438,766
1995-12-06 13D/A REGN / Regeneron Pharmaceuticals, Inc. 1,308,766
1995-09-25 13D/A REGN / Regeneron Pharmaceuticals, Inc. 1,083,766